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ABSTRACT 
 
Rationale: Hypertrophic cardiomyopathy (HCM) is a genetic paradigm of cardiac hypertrophy. Cardiac 
hypertrophy and interstitial fibrosis are important risk factors for sudden death and morbidity in HCM. 
Oxidative stress is implicated in the pathogenesis of cardiac hypertrophy and fibrosis. Treatment with anti-
oxidant N-acetylcysteine (NAC) reverses cardiac hypertrophy and fibrosis in animal models of HCM.  
 
Objective: To determine effect sizes of NAC on indices of cardiac hypertrophy and fibrosis in patients with 
established HCM. 
 
Methods and Results: Hypertrophy Regression with N-AcetyLcysTeine in Hypertrophic CardioMyopathy 
(HALT-HCM) is a double blind randomized, sex-matched, placebo-control single center pilot study in 
patients with HCM. HCM patients, who had a left ventricular wall thickness of 15 mm, were randomized 
either to a placebo or to NAC (1:2 ratio, respectively). NAC was titrated up to 2.4 g per day. Clinical 
evaluation, blood chemistry, and six-minute walk test were performed every 3 months, and 
electrocardiography, echocardiography, and cardiac magnetic resonance imaging (CMR), the latter 
whenever not contraindicated, before and after 12 months of treatment. 85 out of 232 screened patients met 
the eligibility criteria, 42 agreed to participate; 29 were randomized to NAC and 13 to placebo groups. 
Demographics, echocardiographic, and CMR phenotypes at the baseline between the two groups were 
similar. Whole exome sequencing in 38 patients identified a spectrum of 42 pathogenic variants in genes 
implicated in HCM in 26 participants. Twenty-four patients in the NAC and eleven in the placebo groups 
completed the study. Six severe adverse events occurred in the NAC group but were considered unrelated 
to NAC. The effect sizes of NAC on the clinical phenotype, echocardiographic, and CMR indices of cardiac 
hypertrophy, function, and extent of late gadolinium enhancement, a surrogate for fibrosis, were small.  
 
Conclusions: Treatment with NAC for 12-months had small effect sizes on indices of cardiac hypertrophy 
or fibrosis. The small sample size of the HALT-HCM study hinders from making firm conclusions about 
efficacy of NAC in HCM. 
Clinical Trial Registration: NCT01537926 
 
Keywords:  
Hypertrophic cardiomyopathy, hypertrophy, fibrosis, N-acetylcysteine, sudden cardiac death, cardiac 
magnetic resonance imaging,  
 
Nonstandard Abbreviations and Acronyms: 
CADD  Combined annotation dependent 
CMR  Cardiac magnetic resonance imaging 
CVA  Cerebrovascular accident   
ECV  Extracellular volume fraction 
EDV  End diastolic volume 
HCM  Hypertrophic cardiomyopathy 
ITT  Intention to treat 
LGE  Late gadolinium enhancement 
LVED  Left ventricular end diastolic  
LVMI  Left ventricular mass indexed to body surface area 
NAC  N-acetylcysteine 
NYHA  New York Heart Association 
PP  Per protocol 
SCD  Sudden cardiac death 
SNV  Single nucleotide variants 
WES  Whole exome sequencing 
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INTRODUCTION 
 
Hypertrophic cardiomyopathy (HCM) is a hereditary disease of the myocardium caused mainly by 
mutations in genes encoding sarcomere proteins. 1 It is an important cause of sudden cardiac death (SCD) 
in the young and a major cause of morbidity in older individuals, primarily because of cardiac arrhythmias 
and heart failure with preserved ejection fraction. 1 HCM is clinically diagnosed by the presence of 
unexplained left ventricular hypertrophy and pathologically by the presence of myocyte disarray and 
interstitial fibrosis. 1 Cardiac hypertrophy is the quintessential clinical phenotype of human HCM and an 
important determinant of mortality, morbidity and the risk of SCD. 2-5 Likewise, interstitial fibrosis has 
been associated with clinical events, including cardiac arrhythmias in HCM. 6-9 Current pharmacological 
therapies are not effective in preventing, attenuating, or reversing cardiac hypertrophy and fibrosis in HCM.  
 
 Genetic and pharmacological interventions in animal models of HCM have established the potential 
for reversibility of cardiac hypertrophy and fibrosis. 10-15 N-acetylcysteine (NAC) is a precursor to 
glutathione, which is the most abundant intracellular thiol pool against oxidative stress in the body. 
Treatment with NAC has been shown to reverse established cardiac hypertrophy and fibrosis in independent 
studies in animal models of HCM. 15-17 Treatment with NAC also attenuates cardiac hypertrophy induced 
by pressure overload, administration of angiotensin II, and altered myocardial metabolism. 18-20 The 
beneficial effects of NAC in models of cardiac hypertrophy and dysfunction are in accord with the important 
roles of oxidative stress-responsive signaling pathways, myocardial metabolism, and oxidative 
modification of myofilament proteins in the pathogenesis of cardiac hypertrophy. 17 18-20 Extensive clinical 
use and safety profile of NAC in humans and the results of the experimental studies in the animal models 
of HCM, identify NAC as an attractive agent for potentially attenuating and reversing cardiac phenotypes 
in human patients with HCM. The purpose of this feasibility study, dubbed as “Hypertrophy Regression 
with N-AcetyLcysTeine in Hypertrophic CardioMyopathy (HALT-HCM)” was to determine recruitment, 
accrual, retention and compliance rates, tolerability, safety, and side effects, as well as the effect sizes of 
NAC on the indices of cardiac hypertrophy and fibrosis in patients with HCM. 
 
 
 
METHODS 
 
Institutional Review Board of the University of Texas Health Science Center approved the study. Each 
participant signed a consent form. The study was registered at the ClinicalTrials.gov web site 
(NCT01537926). Anonymized data that support the findings of this study are available from the 
corresponding author upon reasonable request 
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Eligibility criteria. 
Eligibility criteria are described in Table 1. In brief, adult patients with an established diagnosis of HCM, 
defined as primary cardiac hypertrophy with a left ventricular end diastolic (LVED) wall thickness of 15 
mm on a 2-dimensional echocardiogram, non-dilated LV cavity, and preserved LV systolic function, were 
considered eligible. Those allergic to NAC, a recent history of septal ablation or plan to undergo myectomy 
in the near future, known phenocopy conditions, and concomitant diseases were excluded. Patients with 
devices, such as pacemakers and cardioverter/defibrillators (ICDs) and those expected to receive a device 
during the course of the study were excluded from the CMR part of the study. 
 
 
 
Data management. 
REDCap (Research Electronic Data Capture) tools, hosted at UTHealth, were used for collecting and 
managing data. REDCap is a secure, web-based application designed to support data capture for research 
studies. 21 
 
Randomization. 
The study statistician prepared a block randomization schedule, which balanced the distribution of patients 
in the study arms 2:1 (NAC group vs. placebo group) and with respect to patient gender. The randomization 
TABLE 
Eligibility Criteria 
 Inclusion criteria: 
o Established diagnosis of HCM, defined as the presence of primary cardiac hypertrophy with a 
left ventricular end diastolic (LVED) wall thickness of 15 mm, a non-dilated LV cavity, and 
preserved LV systolic function on a 2D echocardiogram 
 Exclusion criteria:  
o Hypersensitivity to NAC 
o Individuals younger than 18 years old 
o Known phenocopy conditions 
o History of (with the last 6 months) or planned transcatheter (alcohol) septal ablation or surgical 
myectomy  
o Patients who are likely to receive a pacemaker or an ICD implantation during the study period: 
o Patients with advanced atrioventricular block or severe bradycardia 
o Patients with serious ventricular arrhythmias  
o Known causal mutations but an LVED wall thickness of <15 mm 
o Patients with concomitant diseases 
o Coronary artery disease, defined as >70% luminal diameter stenosis in any of the major 
coronary arteries (if known) 
o Valvular heart diseases (more than mild aortic stenosis and mitral regurgitation 
o Uncontrolled hypertension, defined as systolic blood pressure of ≥140 mmHg and 
diastolic blood pressure of ≥90 mmHg on medication (mean values of three 
measurements at rest) 
o Other significant medical problems, such as moderate to severe chronic renal failure 
(GFR<45 ml/min/1.73m2), advanced liver disease, cancer, or other disabling conditions 
o Pregnant women, nursing mothers and those who plan pregnancy during the study period 
o Patients with active asthma 
o Cardiac contra-indications for MRI (for CMR studies only), including patients with devices 
such as pacemakers and ICDs 
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schedule was provided to the study pharmacist. The data manager regularly checked to ensure proper 
utilization of the randomization program. 
 
Dosing of NAC and placebo. 
NAC was prepared by a compound pharmacy as 600 mg capsules along with identically appearing placebo 
capsules. Active and placebo capsules were coated to minimize the distinction between the two capsules 
based on odor and taste. The compound pharmacy labeled the study drug based on study identification 
number and randomization. NAC was administered at 600 mg orally every 12 hours for the first 3 months 
and then was increased to 1,200 mg twice per day for an additional 9 months. Thus, the total duration of 
treatment with NAC or matching placebo was 12 months.  
 
Compliance. 
Compliance with the study drug was determined by counting the number of unused pills in every visit and 
interviewing the participants. 
 
Genetic analysis. 
Exome sequencing was performed using Illumina sequencing platforms and analyzed by the investigators, 
as described. 22, 23 In brief, the Sequence reads were mapped to the reference Human Genome version 19 
(hg19). Single nucleotide variants (SNVs) and small/insertion deletion (indels) were called according to 
GATK best practices pipeline (https://software.broadinstitute.org/gatk/best-practices/). Functional 
annotation of the variant list for each exome was performed utilizing ANNOVAR software 
(http://annovar.openbioinformatics.org/). Rare variants in 19 genes (ACTC1, ACTN2, CALR3, CSRP3, 
JPH2, MYBPC3, MYH7, MYL2, MYL3, MYOZ2, NEXN, PLN, PRKAG2, TCAP, TNNI3, TNNT2, TPM1, 
TTN, VCL), implicated in familial HCM (https://ghr.nlm.nih.gov/condition/familial-hypertrophic-
cardiomyopathy#genes), were manually curated. Variants meeting the following criteria were considered 
pathogenic.  
1) Minor allele frequency ≤ 0.001, as reported in the Genome Aggregation Database 
(http://gnomad.broadinstitute.org/); 
2) Combined annotation dependent (CADD) phred score, as a measurement of relative 
pathogenicity, of 10 24; and 
3) A minimum of 10 reads covering the candidate variant and the genotype quality of 99 (a Phred-
scaled confidence that the genotype assignment is correct. It is equal to 1% error rate). 
 
Clinical evaluation. 
A medical history was obtained, New York Heart Association functional class was recorded, and physical 
examination was performed in every participant. The participants also completed a 6-minute walk test. A 
blood chemistry panel comprised of electrolytes, BUN, creatinine, liver enzymes and lipids were obtained 
at the baseline and every 3 months until the completion of the study. Twelve-lead electrocardiograms were 
obtained in all participants at baseline and completion of the study. 
 
Echocardiographic imaging and analysis. 
The patients were imaged in the left lateral decubitus position with an ultrasound system equipped with a 
multifrequency transducer. A complete echocardiographic study was performed per standard views. 
American Society of Echocardiography/European Association of Cardiovascular Imaging (ASE/EACVI) 
guidelines were applied to measure biplane LV volumes, mass, and ejection fraction (EF) as well as left 
atrial maximum volume. 25 From the apical window, pulsed-wave Doppler was used to record mitral inflow 
for three to five cardiac cycles at the level of the mitral valve annulus and tips. 26 Pulmonary venous flow 
was recorded using color Doppler guidance. Tissue Doppler (TD) was applied to record mitral annular 
velocities at the septal and lateral sides of the annulus. The resulting annular velocities by pulsed-wave 
Doppler were recorded for five cardiac cycles at a sweep speed of 100 mm/s. Tricuspid regurgitation 
velocity was recorded by continuous wave (CW) Doppler from multiple windows and the peak velocity 
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was noted. Inferior vena caval diameter and its collapse as well as hepatic venous flow were recorded from 
the subcostal views. 27 Echocardiographic measurements were performed offline (Digisonics EC, Houston, 
TX) without knowledge of randomization groups, clinical and CMR findings. 
 
Mitral inflow from tips level was analyzed for peak early (E), and late (A) diastolic velocities, E/A ratio, 
and deceleration time of mitral E velocity. Mitral A duration was measured at the level of mitral annulus. 
26 Pulmonary venous flow was analyzed for peak systolic velocity, peak diastolic velocity, peak amplitude 
and duration of atrial reversal velocity (Ar) and the difference between Ar velocity duration and mitral A 
duration or Ar-A duration. 26 Mitral annulus early (e’) and late (a’) diastolic velocities were measured at 
septal and lateral mitral annulus, and E/e’ ratios were computed. Measurements were averaged over three 
cardiac cycles.  
 
CMR. 
1.5 T whole body imagers were utilized in all cardiac MRI studies. LV cine imaging was performed using 
steady-state free precession sequences in long and short axes with temporal resolution less than or equal to 
40 msec. LV structural and functional measures included LV mass, end diastolic volume (EDV), end 
systolic volume (ESV), EF and stroke volume based on contours of the endocardial and epicardial contours 
of the left ventricle using CMR software (Circle Cardiovascular Imaging, Calgary, Canada). T1 mapping 
of the myocardium before and after 0.15 mmol/kg gadolinium contrast administration was performed. 
Details of the T1 mapping method and cardiac MRI methods using methods that were described previously. 
28 Briefly, T1 mapping indices including pre (native) and post-contrast T1 times at 12 and 25 minutes, 
partition coefficient (), and extracellular volume fraction [ECV=100(1-hematocrit)] were assessed 
using a single-breath hold modified Look-Locker inversion recovery (MOLLI) sequence. 29 Late 
gadolinium enhancement (LGE) images were obtained at the same slice locations as the cine images in the 
short and long axis imaging planes using fast gradient echo imaging beginning 15 minutes after the 
administration of the gadolinium contrast agent. Myocardial scar was defined as focal LGE either in two 
adjacent short axis slices or in one short axis and a long axis image at a corresponding location.  Focal LGE 
was traced using QMass (version 7.2; Medis, Leiden, the Netherlands) to derive myocardial scar mass. 
 
Endpoints. 
The study was a feasibility study, designed primarily to assess the recruitment, retention, and compliance 
rates, the side effects, and the effect sizes of NAC on echocardiographic and CMR indices of cardiac 
hypertrophy and fibrosis. Therefore, changes in left ventricular mass index (LVMI), ventricular wall 
thickness, left ventricular ejection fraction on echocardiography and CMR as well as macroscopic 
interstitial myocardial fibrosis, as defined by delayed enhancement on CMR following gadolinium contrast 
administration, were included as secondary end points. 
 
Statistical analysis. 
Baseline characteristics of patients randomized to the two study groups were compared. Intention-to-treat 
(ITT) analysis was applied to compare the clinical, echocardiographic and CMR outcome variables. This 
was complemented with the per-protocol (PP) analysis to calculate the effect sizes of NAC. For continuous 
variables, normality of the distribution was tested by Shapiro-Wilk test. For continuous variable with 
normal distribution groups were compared using two independent sample t test. Continuous variables with 
non-normal distribution were analyzed with the Kruskal-Wallis test and categorical variables were analyzed 
by the Chi Square test. Changes in outcome variables between the two time-points were analyzed using 
longitudinal analyses (Mixed Models). In these models, interaction analysis was performed to determine if 
the treatment effect varied by phenotype. The effect size of NAC on the echocardiographic and CMR 
indices were calculated as (Placebo - NAC)/SDPlacebo, per Glass’s  method. 30 SAS 9.4 statistical package 
(SAS Institute Inc. USA) was used for data analyses. 
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RESULTS 
 
Recruitment, retention, and compliance. 
 
A total of 232 patients with HCM were screened over a period of 3 years of whom 85 met the 
eligibility criteria and 147 did not (Figure 1). The main reason for exclusion was a LV wall thickness of < 
15 mm (55 patients) on the screening echocardiogram (Figure 1). Twenty-eight of the 85 eligible 
individuals declined to participate and 15 did not respond to the follow-up enrollment invitations. Forty-
two participants (32 males and 10 females) signed inform consents; 29 were randomized to NAC and 13 to 
placebo groups. The baseline demographics of the study population in each group are shown in Table 2. 
There were no significant differences in ages, sexes, ethnic backgrounds, body mass indices, mean systolic 
and diastolic blood pressures and NYHA functional classes or other clinical characteristics between the two 
groups at enrollment with the exception of a history of smoking, which was higher in the NAC group. 
 
TABLE 2 
 
Baseline Characteristics of the Study Population 
 
 Placebo (±SD) NAC (±SD) p Value 
N 13 29 
Male/Female 10/3 22/7 0.94 
Age (years) (mean) 47.6 (15.1) 50.7 (15.0) 0.56
Height (cm)   (mean) 173.1 (11.2) 174.3 (11.4) 0.97 
Weight (Kg) (mean) 89.3 (22.9) 92.6 (19.5) 0.71 
BSA (m2) (mean) 2.07 (0.32) 2.12 (0.27) 0.62 
BMI (Kg/m2) (mean) 29.5 (5.4) 30.4 (5.4) 0.71 
Ethnic: N (%)  
0.57 Hispanic 1 (7.7) 4 (13.8) 
Non-Hispanic 12 (92.3) 25 (86.2) 
Race: N (%) 
0.47 
Caucasian 10 (76.9) 23 (79.4) 
African American 1 (7.7) 4 (13.8) 
Asian or Pacific Islander 2 (15.4) 1 (3.4) 
Mixed 0 (0.0) 1 (3.4) 
NYHA Functional class: N (%) 
0.29 
Class I 5 (38.5) 16 (55.2) 
Class II 5 (38.5) 11 (37.9) 
Class III 3 (23.0) 2 (6.9) 
Class IV 0 (0.0) 0 (0.0) 
Past Medical History (history of) 
Cardiac arrest: N (%) 0 (0) 1 (3.4) 0.50 
Atrial fibrillation: N (%) 2 (15.4) 3 (10.3) 0.64 
Other cardiac arrhythmias: N (%) 8 (61.5) 19 (65.5) 0.80 
Syncope: N (%) 4 (30.1) 8 (27.6) 0.83 
ICD implantation: N (%) 3 (23.1) 11 (37.9) 0.34 
Diabetes mellitus: N (%) 0 3 (10.3) 0.23
Hypertension: N (%) 5 (38.5) 12 (41.4) 0.86
Dyslipidemia: N (%) 5 (38.5) 13 (44.8) 0.70
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Ex-smoker & Current smoking N (%) 1 (7.7) 13 (44.8) 0.02 
History & Physical Examination 
Heart rate (bpm) (mean) 67.2 (11.7) 62.4 (11.2) 0.14 
Systolic blood pressure (mmHg) (mean) 121.2 (14.9) 126.0 (11.7) 0.30 
Diastolic blood pressure (mmHg) (mean) 76.2 (10.8) 79.8 (8.3) 0.41 
Chest pain/tightness: N (%) 5 (17.2) 6 (20.7) 0.23 
Palpitations: N (%)  2 (15.4) 4 (13.8) 0.89 
Systolic ejection murmur: N (%)  5 (38.5) 11 (37.9) 0.97 
Pan-systolic murmur: N (%)  1 (7.7) 4 (13.8) 0.57 
Laboratory  
Total Cholesterol (mg/dL) (mean) 193.5 (54.5) 169.8 (36.5) 0.18
Triglycerides (mg/dL) (mean) 128.6 (55.7) 170.9 (150.4) 0.87
Medication 
Beta-blockers: N (%) 9 (69.2) 20 (69.0) 0.99
Statins: N (%) 3 (23.1) 8 (27.6) 0.76
Anti-arrhythmic drugs: N (%) 1 (7.7) 3 (10.3) 0.79 
RAAS drugs (%) 2 (15.4) 9 (31.0) 0.29
Data are presented as mean SD, unless specified  
For comparison of categorical data p value is based on Chi-Square test or Fisher’s exact test.  
For comparison of continuous data p value is based on Wilcoxon Rank Sum test  
Abbreviations: BSA: Body surface area; BMI: Body mass index; NSVT: Non-sustained ventricular 
tachycardia; VT: Ventricular tachycardia; ICD: internal cardioverter and defibrillator; RAAS: Renin-
angiotensin-aldosterone system  
 
Twenty four out of 29 (83%) patients in the NAC  and 11/13 (85%) in the placebo groups completed 
the 12-month duration of the study. The reasons for drop out were: lost to follow up (4 patients), unable to 
commit time (one patient), non-study related surgical procedure requiring prolonged hospitalization (one 
patient), and skin rash (one patient). Demographics of patients who completed the study did not differ 
between the two groups. Compliance rate, determined by pill counting and patient interview in each visit, 
was high, as the participants consumed 928% (range 66 to 100%) of the prescribed study drug. 
 
Biochemical laboratory values, including blood chemistry, kidney function and liver function tests 
did not significantly change in either of the study groups during the course of 12 months (data not shown).  
 
Pathogenic variants in the known HCM genes. 
 
Thirty-eight of the 42 participants in HALT-HCM study agreed to genetic testing by whole exome 
sequencing (WES). Variant analysis led to identification of 42, including 11 novel (not reported in gnomAD 
database) pathogenic variants in 26 (68%) participants in 19 known genes considered to be causes of HCM 
(Table 3). TTN gene had the highest number of pathogenic variants (23, including 5 novel variants), likely 
reflective of it enormous size, and all were missense variants with a CADD score of >10. Eight pathogenic 
variants, including two indels, leading to frameshift; and one splice junction variant, in the MYBPC3 gene 
were identified in 9 participants. Eleven participants had two or more pathogenic variants in the known 
HCM genes, including one individual, who had 4 pathogenic, including 3 novel variants in the TTN, and 
one pathogenic variant in the MYBPC3 genes. 
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TABLE 3 
 
Pathogenic Variants in the Participants in Known HCM Genes 
 
Gene Variants with reads ≥10, 
Genotype quality = 99 
Number 
of 
individua
ls  
Gnomad 
AF 
CADD 
Phred 
Score 
ClinVar Clinical 
Significance 
ACTC1 NM_005159:exon3:c.C299T: 
p.Pro100Leu 
1 0.000004 23.2 Uncertain 
Significance 
ACTN2 NM_001103:exon16:c.G1864
A: 
p.Asp622Asn 
1 0.0003 35 Conflicting 
interpretations of 
pathogenicity
MYBPC
3 
NM_000256:exon23:c.2373du
pG: 
p.Trp792ValfsTer41 
1 0.000018 NA W792Ter,W792R, 
Pathogenic/ 
Likely pathogenic
MYBPC
3 
NM_000256:exon16:c.G1468
A: 
p.Gly490Arg 
1 0.0002 25.1 Conflicting 
interpretations of 
pathogenicity
MYBPC
3 
NM_000256:exon6:c.G655C: 
p.Val219Leu 
1 Not listed 16.74 Pathogenic/ 
Likely pathogenic 
MYBPC
3 
NM_000256:exon12:c.G1000
A: 
p.Glu334Lys 
1 0.0002 35 Conflicting 
interpretations of 
pathogenicity
MYBPC
3 
NM_000256:exon20:c.1928-
2A>G 
2* Not listed 16.32 Pathogenic 
MYBPC
3 
NM_000256:exon12:c.1028de
lC: 
p.Thr343fs 
1 Not listed NA Pathogenic 
MYBPC
3 
NM_000256:exon22:c.G2308
A: 
p.Asp770Asn 
1 0.000016 35 Pathogenic/ 
Likely pathogenic 
MYBPC
3 
NM_000256:exon16:c.G1484
A: 
p.Arg495Gln 
1 0.00002 27.6 Pathogenic/ 
Likely pathogenic 
MYH7 NM_000257:exon23:c.C2722
G: 
p.Leu908Val 
1 0.00003 18.46 Conflicting 
interpretations of 
pathogenicity
MYH7 NM_000257:exon21:c.G2330
C: 
p.Arg777Thr 
1 Not listed 24.9 Pathogenic 
MYL2 NM_000432:exon2:c.G37A: 
p.Ala13Thr 
3* 0.0003 16.11 Conflicting 
interpretations of 
pathogenicity
TNNT2 NM_000364:exon10:c.C304T: 
p.Arg102Trp 
3* 0.000004 20.9 Pathogenic/ 
Likely pathogenic 
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TTN NM_001267550:exon326:c.G
78394A: 
p.Asp26132Asn 
1 0.000012
25 
15.71  
TTN NM_001267550:exon298:c.G
58491A: 
p.Met19497Ile 
1 Not listed 13.82  
TTN NM_001267550:exon117:c.C
31384A: 
p.Pro10462Thr 
1 0.000001
187 
17.89  
TTN NM_001267550:exon63:c.C1
8389G: 
p.Thr6130Arg 
1 Not listed 12.97  
TTN NM_001267550:exon300:c.C
59315T: 
p.Pro19772Leu 
1 Not listed 10.15  
TTN NM_001267550:exon133:c.G
32743C: 
p.Ala10915Pro 
1 0.000962
0 
12.38  
TTN NM_001267550:exon269:c.C
50758G: 
p.Pro16920Ala 
1 0.000240
0 
14  
TTN NM_001267550:exon358:c.A
106154C: 
p.Lys35385Thr 
1 0.000000
8134 
11.53  
TTN NM_001267550:exon326:c.A
74596G: 
p.Thr24866Ala 
1 0.000203
5 
12.49  
TTN NM_001267550:exon152:c.C
34778T: 
p.Pro11593Leu 
1 0.000008
603 
18.58  
TTN NM_001267550:exon335:c.T
90913C: 
p.Tyr30305His 
1 0.000146
8 
16.06  
TTN NM_001267550:exon358:c.C
101281T: 
p.Arg33761Trp 
1 0.000093
94 
16.42  
TTN NM_001267550:exon345:c.G
95743A: 
p.Ala31915Trp 
1 Not listed 12.5  
TTN NM_001267550:exon326:c.C
85471T: 
p.Arg28491Cys 
1 0.000050
74 
13.89 Uncertain 
Significance 
TTN NM_001267550:exon318:c.G
67318A: 
p.Gly22440Ser 
1 Not listed 11.25  
TTN NM_133379:exon46:c.T1128
9A: 
p.Asp3763Glu 
1 Not listed 16  
TTN NM_001267550:exon318:c.A
67104C: 
3* 0.000049 10.46  
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p.Lys22368Asn 
TTN NM_001267550:exon326:c.G
82810A: 
p.Gly27604Ser 
1 0.000478
3 
23.8 p.Gly27604Arg: 
Uncertain 
Significance
TTN NM_001267550:exon28:c.C5
198T: 
p.Thr1733Met 
1 0.000264
0 
11.69 Uncertain 
Significance 
TTN NM_001267550:exon358:c.A
103591G: 
p.Lys34531Glu 
1 0.000073
14 
13.21  
TTN NM_001267550:exon324:c.G
68864C: 
p.Gly22955Ala 
1 0.000254
7 
12.56  
* Family members 
 
Abbreviations: ACTC1: Cardiac  actin; ACTN2:  Actinin 2; MYBPC3: Myosin binding protein C3; 
MYH7: Myosin heavy chain Y; MYL2: Myosin light chain 2; TNNT2: Cardiac troponin T; TTN: Titin; AF: 
allele frequency; CADD: Combined Annotation Dependent Depletion  
 
Clinical symptoms. 
 
Ten out of 13 and 27/29 participants in the placebo and NAC groups, respectively, were in NYHA 
functional class I or II (Online Table I). Only 5 patients in the study population were in class III and none 
in class IV (Online Table I). Distribution of patients among NYHA functional classes did not differ 
significantly between the placebo and NAC groups at the baseline and during the follow up intervals (Online 
Table I). The change in NYHA functional class status of each patient during each follow up interval is 
illustrated in Online Figure I. Frequency or severity of chest pain and palpitations did not change during 
the study period (data not shown). No patient experienced syncope or near syncope during the study period. 
All participants completed a 6-minute walk test without experiencing notable symptoms. There were no 
differences in the mean distance walked at the baseline and the follow up time points between the two 
groups (Online Figure II).  
 
Electrocardiographic indices. 
 
There were no significant differences in the electrocardiographic findings, including indices of 
cardiac hypertrophy at the baseline or upon completion of the study (Online Table II). 31 
 
Echocardiographic phenotypes. 
 
Indices of left ventricular wall thickness, size, and function were not different between the placebo 
and NAC groups at baseline and upon completion of the study (Table 4 and Online Table III). 
Echocardiographic data in those who had baseline and 12-months studies were used to calculate the effect 
sizes. The effect sizes of NAC on indices of cardiac hypertrophy and function, including Doppler indices 
of left ventricular function were negligible to modest (Table 4). Likewise, when all patients who 
participated in the study were included in the analysis (intention to treat analysis), there were no discernible 
differences in echocardiographic or Doppler indices of left ventricular size and function between the  
placebo and NAC groups in a model that included interaction between the study groups and the follow up 
time (Online Table III).  
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TABLE 4 
 
Echocardiographic Phenotypes (Per-Protocol analysis) 
 
 Placebo NAC 
p 
Placebo
-NAC* 
(95% 
CI) 
SE Effect size 
N 11 24
M/F 9/2 18/6
Age 
(year) 49.35 (15.21) 50.18 (15.86) 
 Baseline 
Follow
-up 
Delta(
) 
Baselin
e 
Follow
-up 
Delta(
) 
Body 
weight 
(Kg) 
88.03 
(23.30) 
89.44 
(22.70) 1.40 
90.82 
(16.91) 
92.94 
(17.96) 2.12 
0.7
4 
1.58 
(-2.82, 
4.25) 
2.16 0.11 
BSA 
(m2) 
2.05 
(0.32) 
2.07 
(0.32) 0.02 
2.1 
(0.23) 
2.12 
(0.25) 0.02 
0.9
3 
0.00 
(-0.04, 
0.05) 
0.03 0.07 
IVST 
(mm) 
18.00 
(3.97) 
17.82 
(4.87) -0.18 
18.88 
(4.59) 
17.92 
(3.3) -0.96 
0.5
7 
0.78 
(-0.78, 
-3.53) 
1.35 0.23 
LVPWT 
(mm) 
13.55 
(3.59) 
13.27 
(3.8) -0.27 
12.29 
(2.69) 
13.79 
(1.96) 1.50 
0.0
9 
1.77 
(-0.31, 
3.85) 
1.02 0.53 
Maximu
m wall 
thickness 
(mm) 
20.55 
(3.24) 
20.55 
(4.11) 0.00 
20.54 
(4.42) 
19.75 
(2.92) -0.79 
0.4
7 
0.79 
(-2.97, 
1.39) 
1.07 0.30 
LVEDD 
(mm) 
39.36 
(6.42) 
39.91 
(2.7) 0.55 
39.38 
(7.41) 
39.83 
(6.34) 0.46 
0.9
7 
0.09 
(-5.37, 
5.20) 
2.60 0.01 
LVESD 
(mm) 
22.64 
(5.16) 
21.55 
(3.8) -1.09 
22.13 
(6.06) 
21.88 
(5.29) -0.25 
0.7
2 
0.84 
(-3.89, 
5.57) 
2.32 0.14 
EF (%)-
mean 
69.45 
(6.53) 
68.55 
(5.17) -0.90 
69.23 
(6.80) 
69.44 
(6.12) 0.22 
0.5
9 
1.12 
(-3.00, 
5.24) 
2.02 0.20 
LA 
Volume 
(ml) 
74.62 
(27.34) 
83.58 
(27.83) 9.45 
89.50 
(26.7) 
86.08 
(31.63) 0.89 
0.3
3 
8.56 
(-
28.63, 
11.52) 
9.72 0.49 
LVM (g) 
292.80 
(107.50
) 
290.44 
(99.81) -2.36 
269.65 
(94.17) 
281.98 
(81.75) 12.33 
0.5
6 
14.69 
(-
36.32, 
65.69) 
25.1
0 0.23 
LVMI 
(g/m2) 
141.95 
(50.14) 
140.41 
(47.27) -1.55 
128.48 
(43.60) 
132.92 
(35.41) 4.45 
0.6
3 
5.99 
(-
19.10, 
31.10) 
12.3
3 0.19 
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E (cm/s) 79.04 (18.16) 
77.55 
(14.24) 4.19 
70.53 
(20.23) 
74.79 
(22.4) 3.81 
0.8
5 
0.38 
(-
10.95, 
10.19) 
5.16 0.02 
A (cm/s) 71.00 (25.50) 
64.29 
(31.31) 1.58 
63.04 
(26.07) 
61.36 
(24.09) -2.09 
0.8
6 
0.367 
(-
19.61, 
12.77) 
7.77 0.20 
E/A  1.28 (0.67) 
1.40 
(0.54) 0.09 
1.27 
(0.46) 
1.38 
(0.56) 0.13 
0.9
4 
0.04 
(-0.67, 
0.75) 
0.24 0.05 
IVRT 
(msec) 
85.64 
(12.85) 
86 
(18.77) -2.00 
82.25 
(13.87) 
87.79 
(20.86) 2.14 
0.5
9 
4.14 
(-
16.19, 
24.48) 
9.78 0.16 
Septal Sa 
(cm/s) 
5.49 
(1.89) 
4.69 
(1.79) -1.38 
5.16 
(0.83) 
4.26 
(1.63) -0.88 
0.6
3 
0.50 
(-1.27, 
2.27) 
0.83 0.39 
Septal 
Ea 
(cm/s) 
4.49 
(2.05) 
5.17 
(1.48) -0.02 
4.79 
(1.42) 
4.45 
(1.61) -0.04 
0.4
8 
0.02 
(-1.68, 
1.64) 
0.77 0.03 
Lateral 
Sa 
(cm/s) 
5.13 
(2.39) 
4.53 
(1.69) -0.28 
5.53 
(1.51) 
5.05 
(1.84) 0.08 
0.7
4 
0.36 
(-1.33, 
2.05) 
0.78 0.23 
Lateral 
Ea 
(cm/s) 
6.17 
(2.10) 
9.14 
(3.27) 2.36 
7.00 
(2.16) 
6.36 
(2.35) 0.24 
0.0
2 
2.12 
(-5.44, 
1.21) 
1.53 0.64 
E/e’ ratio 18.80 (9.14) 
15.63 
(6.33) -0.47 
15.26 
(4.63) 
18.97 
(9.59) 1.88 
0.2
1 
2.35 
(-5.40, 
10.10) 
3.69 0.53 
LVOT 
Gradient 
at rest 
(mmHg) 
10.45 
(23.44) 
15.73 
(28.44) 5.27 
14.81 
(25.14) 
15.75 
(25.02) 1.62 
0.6
5 
3.65 
(-
22.05, 
14.75) 
8.98 0.14 
SAM: N 
(%) 1 (9.09) 
3 
(27.27) 2 
3 
(12.50)
5 
(20.83) 2 NA NA NA  NA  
 
All data are presented as mean (SD), unless specified 
* Absolute value of Placebo-NAC 
Abbreviations: NAC: N-acetylcysteine; M/F: Male/females; CI: Confidence interval; SE: Standard Error; 
BSA: Body surface area; IVST: Interventricular septal thickness; LVPWT: Left ventricular posterior wall 
thickness; LVEDD: Left ventricular end diastolic diameter; LVESD: Left ventricular end systolic diameter; 
LVEF: Left ventricular ejection fraction; LA: left atrium; LVM: Left ventricular mass; LVMI: Left 
ventricular mass indexed to body surface area; E: Mitral valve early inflow velocities; A: Mitral valve 
inflow late velocities; IVRT: Isovolumic relaxation time; Septal Sa: Systolic mitral annulus velocity 
measured at septal side of the mitral annulus; Septal Ea: Early diastolic mitral annulus velocity measured 
at septal side of the mitral annulus; Lateral Sa: Systolic mitral annulus velocity measured at lateral side of 
the mitral annulus; Lateral Ea: Early diastolic mitral annulus velocity measured at lateral side of the mitral 
annulus; LVOT: left ventricular outflow tract gradient; SAM: Systolic anterior motion of the mitral leaflet; 
CI: Confidence interval; SE: Standard error. 
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CMR. 
 
Data were available in 9 and 15 patients at the baseline in the placebo and NAC groups, 
respectively, and in 8 and 10 patients at both time points. Data in those who had the baseline and follow up 
data were used to calculate the effect sizes of NAC on indices of cardiac hypertrophy, fibrosis, and fibrosis 
(LGE). As shown in Table 5, no large effect sizes on cardiac mass, LVEF, left ventricular mid wall strain, 
and fibrosis were detected. Likewise, indices of left ventricular wall thickness, cavity size, and function as 
well as mass were not significantly different between the two groups at baseline and upon completion of 
the study in the intention to treat analysis (Online Table IV). 
 
TABLE 5 
 
Cardiovascular Magnetic Resonance (CMR) Phenotypes (Per-Protocol analysis) 
 
 Placebo NAC 
p 
Placebo-
NAC* 
(95% 
CI) 
SE
Eff
ect 
siz
e 
N 8 10
M/F 7/1 7/3
Age (year) 50.1 (17.9) 48.9 (16.2)
 Baseline Follow-up 
Delta
() Baseline 
Follow-
up 
Delta
() 
MWT 
(mm) 
16.95 
(5.66) 
17.58 
(4.01) 0.63 
16.80 
(4.77) 
17.75 
(6.05) 0.95 
0.8
1 
0.33 
(-2.55, 
3.20) 
1.3
6 
0.1
2 
LVEDV 
(ml) 
181.42 
(43.85) 
175.13 
(47.92) -6.29 
180.9 
(33.31) 
179.0 
(41.31) -1.90 
0.5
3 
4.39 
(-10.29, 
19.07) 
6.9
2 
0.3
2 
LVESV 
(ml) 
78.20 
(27.82) 
79.25 
(30.89) 1.06 
75.7 
(18.61) 
77.2 
(24.29) 1.50 
0.9
3 
0.45 
(-9.78, 
10.67) 
4.8
2 
0.0
4 
LVEF (%) 57.48 (9.00) 
55.00 
(10.95) -2.48 
58.1 
(7.11) 57 (8.03) -1.10 
0.5
0 
1.38 
(-2.81, 
5.56) 
1.9
8 
0.2
7 
Mean LV 
mid wall 
strain (%) 
-13.86 
(3.73) 
-15.86 
(3.75) -2.16 
-15.22 
(2.66) 
-14.78 
(2.37) 0.44 
0.0
5 
0.74 
(-1.09,  
6.30) 
1.2
5 
0.0
8 
Myocardia
l Mass (g) 
207.83 
(82.38) 
221.29 
(87.65) -1.67 
214.89 
(97.68) 
238.22 
(99.72) 41.25 
0.4
8 
42.92 
(-44.51, 
130.30) 
43.
32 
2.8
3 
EM (g) 53.67 (45.03) 
51.43 
(25.53) -5.17 
29.67 
(16.86) 
38.00 
(18.57) 7.00 
0.3
2 
12.17 
(-13.98, 
38.31) 
12.
00 
0.4
6 
EV (%) 22.50 (15.14) 
22.29 
(5.88) -0.17 
13.89 
(5.25) 
16.67 
(7.84) 1.50 
0.6
4 
1.67 
(-9.58, 
12.92) 
5.1
6 
0.1
4 
All data are presented as Mean (SD), unless specified. p values are per mixed model analysis 
* Absolute value of  Placebo-NAC 
Abbreviations: NAC: N-acetylcysteine; M/F: Male/females; MWT: Maximum wall thickness; LVEDV: 
Left ventricular end diastolic volume; LVESV: Left ventricular end systolic volume; LVEF: Left 
ventricular ejection fraction; LA: left atrium; EM: Enhanced myocardium; EV: Percent of myocardium 
that has scar (percentage EM/MM); CI: Confidence interval; SE: Standard error 
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Adverse and serious adverse effects. 
 
There was no adverse event. A total of 6 serious adverse events in 5 individuals were recorded in 
the study population and all occurred in the NAC group (Fisher exact test p=0.155). Two patients developed 
pneumonia requiring treatment with antibiotics, two patients developed a cerebrovascular accident (CVA), 
including one who had prior episodes of CVAs and subsequently developed seizure. One patient developed 
chest pain, which was determined not to be of cardiac origin. None of the serious adverse events was judged 
to be the known side effect of the study drug.  
 
 
 
DISCUSSION 
 
The results of HALT-HCM, a single center randomized placebo-controlled feasibility study, were 
notable for a relatively slow accrual rate of HCM patients but a high retention and compliance rates upon 
enrollment. About one fifth of the 232 patients (42 patients) who were screened were recruited and 
randomized. The compliance and retention rates at 12-month were high, which are notable considering that 
most patients were asymptomatic or mildly symptomatic and did not have strong incentive to take the study 
medication and undergo testing. The recruitment, retention, and compliance rates in a single center study 
of HCM, which is an uncommon disease, might reflect the referral basis of the study population. The 
findings also document the effect sizes of NAC on echocardiographic and CMR indices of cardiac 
hypertrophy and fibrosis, which were relatively modest. The study sample size did not provide sufficient 
power to determine efficacy of NAC in treatment of patients with HCM, except for detecting large changes 
in the indices of cardiac hypertrophy and fibrosis. Overall, the findings have implications for the design of 
future efficacy studies in patients with HCM.  
 
The small sample size of the study prohibits from making firm conclusions about efficacy of NAC 
in HCM. Nevertheless, the effect sizes of NAC, administered for one year at a high dose, on the 
echocardiographic and CMR indices of cardiac hypertrophy and fibrosis were relatively small. The findings 
were concordant, regardless of whether the data were analyzed by the ITT or PP approaches. Because the 
study was performed in patients with established cardiac hypertrophy and fibrosis, the findings might not 
pertain to evolving cardiac hypertrophy and fibrosis or prevention of the phenotype in HCM. Modest 
statistical differences in a few echocardiographic indices, including tissue Doppler indices of left ventricular 
function were noted between the baseline and follow up data in the placebo and treatment groups. However, 
these differences did not follow a concordant pattern with the related phenotypes and were not consistent 
across imaging modalities to suggest a clinical significance. Moreover, no changes in the clinical symptoms 
and exercise tolerance in a 6-min walk test were observed, albeit most patients were asymptomatic or 
minimally symptomatic and did not have exercise intolerance. There were a higher number of adverse 
events in the NAC group, but the adverse events did not seem to be related to administration of NAC.  
 
 HALT-HCM was designed as a pilot feasibility study and not an efficacy study, It was designed to 
provide information on recruitment, retention and compliance rates as well as tolerability and the effect 
sizes of NAC on indices of cardiac hypertrophy and fibrosis for designing future efficacy studies. The plan 
was to recruit 25 patients to the placebo and 50 patients to the NAC groups. However, only 42 patients 
participated in one-year long HALT-HCM study. Approximately, half of the eligible patients, who were 
mostly asymptomatic or mildly symptomatic, declined to participate (Figure 1). Data collected from those 
who completed the one-year study were used to determine estimates and 95% confidence intervals for the 
effect size of NAC on echocardiographic and CMR indices of cardiac hypertrophy, function, and fibrosis. 
These effect sizes were small (Tables 4 and 5). A post-hoc analysis showed that  the sample size of the 
study provided 66% to detect 20% (26 g/m2) change and 84% power to detect a 25% (33 mg/m2) change in 
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the mean LVMI, when α is set at 0.05. The study did not have sufficient power to detect smaller changes, 
which might be more realistic, given the slow development of cardiac hypertrophy in HCM. Overall, the 
small sample size of the study on indices of cardiac hypertrophy and fibrosis in HCM suggest that designing 
and implementation of large-scale efficacy studies with NAC would be challenging. 
 
HCM is a genetically and clinically heterogeneous disease. The spectrum of putative causal genes 
and mutations in the study participants were in accord with the known genetic heterogeneity of HCM. 1 The 
abundance of the pathogenic variants in TTN was notable but likely reflects the enormous size of its main 
transcript, coding for ~ 35,000 amino acids. Likewise, several individuals had multiple pathogenic variants 
in genes known to cause HCM, which is in keeping with the oligogenic basis of a subset of HCM patients. 
23 The variants were novel or rare (<1:1000 population frequency in the gnomeAD database) and were 
considered pathogenic. However, given the study participants were either sporadic cases or members of 
small families, causality of these variants in HCM could not be ascertained unambiguously. This is 
particularly the case for the pathogenic variants in the TTN gene, because of the abundance of the non-
synonymous and truncating TTN variants in the general population. 32 Consequently, the pathogenic 
variants in the TTN gene identified in the HALT-HCM population may not be the true causes of HCM in 
this population and/or might simply contribute or modify expression of the phenotype. 33, 34 Nevertheless, 
a subgroup analysis in those carrying pathogenic variants in the TTN gene also showed no discernible effect 
of NAC on cardiac phenotype in HCM (Online Table V). Give the small number of the participants with 
each pathogenic variant and other genes, no additional gene-dependent analysis was performed.  
 
The null findings of the study with regards to the effects of NAC on cardiac hypertrophy and 
fibrosis are in discord with the results of experimental studies in animal models of HCM, where treatment 
with NAC was highly effective in attenuating established hypertrophy and fibrosis. 15-17 Such conflicting 
findings also have been observed in studies of other pharmacological interventions in HCM, including 
studies with statins and inhibitors of the renin-angiotensin-aldosterone system, where the efficacy of these 
pharmacological agents in treatment of human patients with HCM has  not been substantiated, despite the 
beneficial effects in animal models of HCM. 10, 11, 13, 35 The differences in the results of experimental 
therapies in model organisms and clinical trials in humans are likely multifarious and not uncommon. 36-38 
The differences in part may reflect extreme genetic heterogeneity of human patients with HCM, as opposed 
to the model organisms, where a single genetic mutation is introduced in a congenic background to induce 
the phenotype. Likewise, numerous other biological differences between humans and model organisms, 
including the confounding effects of the environmental factors and microbiome. 37 Finally, shortcomings 
of the study design in some of the experimental studies, such as introduction of unconscious biases in group 
assignment, data acquisition, and interpretation might contribute to failure to extend the findings in the 
model organisms to humans. 36, 39 
 
In conclusions, the results of the HALT-HCM, a pilot feasibility study, showed small effect sizes 
of treatment with a high dose of NAC for 12 months on indices of cardiac hypertrophy and fibrosis in 
patients with established HCM. A higher number of adverse events occurred in the NAC group, but these 
events did not seem to be related to administration of NAC. The small sample size of the study did not 
enable assessing efficacy of NAC. Data on recruitment, retention, compliance and the effect sizes of NAC 
on indices of cardiac hypertrophy and fibrosis might provide guidance in designing efficacy studies in 
HCM. 
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FIGURE LEGENDS 
Figure 1. Consort chart showing screening, recruitment, and randomization process 
*  Some individuals had more than one exclusion criteria. 
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NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
 Hypertrophic cardiomyopathy is caused mainly by mutations in genes encoding sarcomere 
proteins. 
 
 Cardiac hypertrophy and fibrosis, important determinants of clinical outcomes, are considered 
secondary to the activation of numerous trophic and mitotic pathways, including oxidative stress-
responsive mechanisms. 
 
 Studies in animal models of HCM have shown that cardiac hypertrophy and fibrosis are reversible 
upon pharmacological interventions, including treatment with N-acetylcysteine (NAC), a precursor 
to glutathione. 
 
What New Information Does This Article Contribute? 
 
  “Hypertrophy Regression with N-AcetyLcysTeine in Hypertrophic CardioMyopathy” (HALT-
HCM) is a double blind randomized, sex-matched, placebo-control study (N=42 patients) designed 
to test feasibility and determine effect sizes of NAC on indices of cardiac hypertrophy and fibrosis 
in patients with established HCM.  
 
 Recruitment rate was slow but retention and compliance rates were high. 
 
 About 2/3 of the participants had one or more pathogenic variants in genes known to cause HCM   
 Treatment with a high dose of NAC for 12 months had negligible to modest effect sizes on indices 
of cardiac hypertrophy and fibrosis in patients with established HCM. 
 
HCM is an important cause of sudden cardiac death in the young and heart failure with preserved ejection 
fraction. There is no effective pharmacological treatment for reversing or preventing cardiac hypertrophy 
and fibrosis in patients with HCM. Pharmacological interventions in animal models of HCM have shown 
reversibility of cardiac hypertrophy and fibrosis upon treatment with NAC. The findings in human patients, 
however, are notable for negligible or modest effect sizes on indices of cardiac hypertrophy and fibrosis. 
The small sample size of the study may have precluded firm conclusions about the efficacy of NAC in 
treatment of patients with HCM.  
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Online Figure I. Heat maps showing changes in New York Heart Association Functional Class in each individual at four 
time points. No significant difference was noted in any of the four time points in NYHA functional classes between the 
placebo and N-acetylcysteine groups. Each horizontal line indicate one individual.  The number in each box indicates 
NYHA functional class. X indicates missing data.
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were no differences between the two groups in the distance walked in 6 minutes at the 
baseline and three follow up time points. Mean and SD data are shown.
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ONLINE TABLE I 
 
New York Heart Association Functional Class at the Baseline and Follow up Time Points 
  Placebo (N=13) NAC (N=29) 
  Baseline 3 months 6 months 12 months Baseline 3 months 6 months 12 months 
Class I 5 9 8 9 16 18 18 14 
Class II 5 3 3 2 11 5 6 9 
Class III 3 0 0 0 2 0 0 1 
Class IV 0 0 0 0 0 0 0 0 
 
 
ONLINE TABLE II 
 
Electrocardiogram Phenotypes (Intention-to-treat analysis) 
 
 Placebo  NAC  Interaction 
 Baseline 12 Months p Baseline 12 Months p p 
N 13 11  29 24   
M/F 10/3 9/2  22/7 18/6   
Age (years) 47.6 (15.1) 50.35 (15.2)  50.7 (15.0) 51.15 (15.8)  0.04 
Body weight (Kg) 89.3 (22.9) 89.4 (22.7) 0.22 92.6 (19.5) 92.9 (18.0) 0.14 0.75 
BSA (m2) 2.07 (0.33) 2.07 (0.32) 0.16 2.12 (0.27) 2.12 (0.25) 0.31 0.93 
Heart rate (bpm) 13 66.2 (11.8) 11 60.4 (11.4) 0.06 29 62.4 (11.2) 24 61.1 (10.7) 0.49 0.14 
Atrial Fibrillation/ 
Flutter (N) 13 0 10 0 NA 28 1 22 1 NA NA 
Paced rhythm (N) 13 0 10 1 NA 28 1 22 3 0.15 0.94 
Conduction defect 
(N)  13 4 10 2 0.24 28 9 22 9 0.32 0.12 
Pathological Q waves 
(N) 13 1 10 1 0.84 28 5 22 2 0.43 0.54 
Left ventricular 
hypertrophy (N) 13 6 10 7 0.27 28 20 22 19 0.16 0.71 
QT interval (mean) 13 444.1 (37.7) 10 452.6 (33.0) 0.18 29 458.4 (37.4) 24 448.8 (37.0) 0.12 0.053 
ST & T abnormalities 
(N) 11 12 10 8 0.44 28 20 22 16 0.61 0.47 
LVH Score - Estes  13 6.2 (4.0) 10 6.2 (3.8) 0.23 29 5.7 (3.0) 24 6.0 (2.9) 0.70 0.48 
 
All data are presented as mean (SD), unless specified 
 
Abbreviations: M/F: Male/Female; NAC: N-acetylcysteine; BSA: Body surface area; LVH: Left ventricular hypertrophy; 
ONLINE TABLE III 
 
Echocardiographic Phenotypes (Intention-to-treat analysis) 
 
 Placebo  NAC  Interaction 
 Baseline 12 Months p Baseline 12 Months p p 
N 13 11  29 24   
M/F 10/3 9/2  22/7 18/6   
Age (years)  47.6 (15.1) 50.35 (15.2)  50.7 (15.0) 51.15 (15.8)  0.04 
Body weight (kg) 89.3 (22.9) 89.4 (22.7) 0.22 92.6 (19.5) 92.9 (18.0) 0.14 0.75 
BSA (m2) 2.07 (0.33) 2.07 (0.32) 0.16 2.12 (0.27) 2.12 (0.25) 0.31 0.93 
Echocardiographic 
Phenotypes N Mean N Mean  N Mean N Mean   
IVST (mm) 13 17.08 (4.35) 11 17.82 (4.87) 0.94 29 18.45 (4.30) 24 17.92 (3.30) 0.34 0.44 
LVPWT (mm) 13 13.08 (3.48) 11 13.27 (3.80) 0.92 29 12.41 (2.67) 24 13.79 (1.96) 0.008 0.15 
Maximum wall 
thickness (mm) 13 19.77 (3.56) 11 20.54 (4.11) 0.98 29 20.00 (4.25) 24 19.75 (2.92) 0.39 0.39 
LVEDD (mm) 13 40.15 (6.34) 11 39.91 (2.70) 0.93 29 40.03 (7.52) 24 39.83 (6.34) 0.98 0.99 
LVESD (mm) 13 23.31(5.25) 11 21.55 (3.80) 0.35 29 22.24 (5.77) 24 21.88 (5.29) 0.79 0.57 
LVEF (%)-mean 13 69.56 (6.03) 11 68.55 (5.17) 0.56 29 69.59 (6.22) 24 69.44 (6.12) 0.95 0.61 
LA Volume (ml) 11 69.47 (27.02) 9 83.58 (27.83) 0.11 25 87.85 (28.00) 19 86.08 (31.63) 0.96 0.28 
LVM (g) 13 281.66 (103.04) 11 290.44 (99.81) 0.98 29 
270.78 
(94.98) 24 
281.98 
(81.75) 0.41 0.67 
LVMI (g/m2) 13 136.78 (49.65) 11 140.41 (47.27) 0.98 29 
127.67 
(42.70) 24 
132.92 
(35.41) 0.49 0.73 
E (cm) 10 79.17 (16.25) 11 77.55 (14.24) 0.85 28 71.85 (19.00) 23 74.79 (22.40) 0.10 0.81 
A (cm) 10 70.61 (23.40) 11 64.29 (31.31) 0.78 27 66.06 (26.20) 22 61.36 (24.09) 0.48 0.81 
E/A ratio 10 1.27 (0.61) 11 1.40 (0.54) 0.61 27 1.22 (0.44) 22 1.38 (0.56) 0.16 0.88 
IVRT (msec) 12 84.42 (12.96) 9 86.00 (18.77) 0.70 19 82.84 (12.90) 19 87.79 (20.86) 0.38 0.71 
Septal Sa (cm/s) 10 5.42 (1.79) 7 4.69 (1.79) 0.03 18 5.19 (1.09) 16 4.26 (1.63) 0.046 0.67 
Septal Ea (cm/s) 10 4.63 (1.98) 7 5.17 (1.48) 0.54 19 4.65 (1.44) 15 4.45 (1.61) 0.72 0.59 
Lateral Sa (cm/s) 9 5.38 (2.18) 7 4.53 (1.69) 0.43 19 5.56 (1.64) 14 5.05 (1.84) 0.60 0.68 
Lateral Ea (cm/s) 9 6.92 (2.51) 7 9.14 (3.27) 0.06 18 7.09 (2.25) 14 6.36 (2.35) 0.50 0.04 
E/e’ ratio 9 18.48 (8.57) 8 15.62 (6.33) 0.66 22 16.87 (8.62) 19 18.97 (9.59) 0.30 0.32 
LVOT Gradient at 
rest (mmHg) 13 8.85 (21.76) 11 15.73 (28.44) 0.46 25 13.12 (23.48) 22 15.75 (25.02) 0.69 0.63 
SAM: N (%) 10 1 (10.0) 10 4 (40) 0.23 20 6 (25) 19 5 (26.35) 0.85 NA 
 
All data are presented as mean (SD), unless specified 
 
Abbreviations: NAC: N-acetylcysteine; M/F: Male/females; CI: Confidence interval; SE: Standard Error; BSA: Body surface area; IVST: 
Interventricular septal thickness; LVPWT: Left ventricular posterior wall thickness; LVEDD: Left ventricular end diastolic diameter; LVESD: Left 
ventricular end systolic diameter; LVEF: Left ventricular ejection fraction; LA: left atrium; LVM: Left ventricular mass; LVMI: Left ventricular 
mass indexed to body surface area; E: Mitral valve early inflow velocities; A: Mitral valve inflow late velocities; IVRT: Isovolumic relaxation time; 
Septal Sa: Systolic mitral annulus velocity measured at septal side of the mitral annulus; Septal Ea: Early diastolic mitral annulus velocity measured 
at septal side of the mitral annulus; Lateral Sa: Systolic mitral annulus velocity measured at lateral side of the mitral annulus; Lateral Ea: Early 
diastolic mitral annulus velocity measured at lateral side of the mitral annulus; LVOT: left ventricular outflow tract gradient; SAM: Systolic anterior 
motion of the mitral leaflet. 
ONLINE TABLE IV 
 
CMR Phenotypes (Intention-to-treat analysis) 
 
 Placebo NAC Interaction 
 Baseline 12 Months p Baseline 12 Months p p 
N 9 8  15 10   
M/F 7/2 7/1  12/3 7/3   
Age (years)  47.6 (18.4) 51.1 (17.9)  48.0 (14.8) 49.9 (16.2)  0.22 
Body weight (Kg)  84.2 (17.1) 85.8 (16.4) 0.45 90.4 (18.1) 93.6 (17.7) 0.08 0.27 
BSA (m2)  1.98 (0.24) 2.03 (0.24) 0.30 2.08 (0.25) 2.11 (0.25) 0.21 0.47 
CMR N Means N Means  N Means N Means   
MWT (mm)  9 16.40 (5.54) 8 17.58 (4.01) 0.38 15 16.14 (4.11) 10 17.75 (6.05) 0.37 0.80 
LVEDV (ml) 9 175.48 (44.71) 8 175.13 (47.92) 0.21 15 177.20 (36.43) 10 179.00 (41.31) 0.60 0.51 
LVESV (ml) 9 76.28 (26.65) 8 79.25 (30.89) 0.80 15 73.67 (17.01) 10 77.20 (24.29) 0.73 0.93 
LVEF (%) 9 56.98 (8.55) 8 55.00 (10.95) 0.20 15 58.27 (6.19) 10 57.00 (8.03) 0.30 0.48 
Mean LV mid wall 
strain (%) 8 -14.8 (3.50) 7 -15.86 (3.74) 0.16 15 -15.32 (2.24) 10 -14.78 (2.37)  0.32 0.04 
Myocardial Mass (g) 7 191.86 (86.27)  7 221.29 (87.65)  0.85 14 211.21 (85.10)  9 238.22 (99.72) 0.33 0.56 
EM (g) 7 48.00 (43.75)  7 51.43 (25.53)  0.75 14 27.57 (15.37)  9 38.00 (18.57) 0.14 0.35 
EV (%) 7 21.29 (14.19)  7 22.29 (5.88)  0.89 14 12.93 (5.10)  9 16.67 (7.84) 0.30 0.59 
All data are presented as Mean (SD), unless specified 
 
Abbreviations: CMR; Cardiac magnetic resonance; NAC: N-acetylcysteine; M/F: Male/Female; BSA: Body surface area; MWT: Maximum wall 
thickness; LVEDV: Left ventricular end diastolic volume; LVESV: Left ventricular end systolic volume; LVEF: Left ventricular ejection fraction; 
LV: Left ventricle; EM: Enhanced myocardium; EV: Percent of myocardium that has scar (percentage of EM/MM) 
 
Online Table V 
 
Echocardiographic Phenotypes in Participants with Pathogenic Variants in TTN Gene 
 
 Placebo NAC 
p D
Placebo-DNAC* 
(95% CI) 
standard 
error 
Effect 
size 
N 6 6 
M/F 5/1 4/2 
Age (year) 49.40 (13.17) 53.888 (16.50) 
 Baseline Follow-up Delta (D) Baseline Follow-up Delta (D) 
Body 
weight (Kg) 88.98 (18.50) 91.41 (17.56) 2.42 90.65 (16.48) 91.78 (18.44) 1.14 0.62 
1.29 
(-6.90, 4.32) 2.52 0.32 
BSA (m2) 2.08 (0.28) 2.12 (0.28) 0.03 2.1 (0.25) 2.08 (0.26) 0.02 0.66 0.02 (-0.10, 0.07) 0.04 0.32 
IVST (mm) 18.17 (2.64) 17.50 (3.02) -0.67 20.33 (3.98) 19.33 (3.78) -1.00 0.77 0.33 (-2.75, 2.08) 1.09 0.24 
LVPWT 
(mm) 11.50 (3.21) 12.50 (4.72) 1.00 12.50 (1.64) 14.33 (2.66) 1.83 0.65 
0.83 
(-3.17, 4.84) 1.80 0.22 
Maximum 
wall 
thickness 
(mm) 
19.33 (3.44) 19.17 (4.49) -0.17 23.00 (4.82) 20.50 (2.74) -2.50 0.28 2.33 (-6.87, 2.207) 2.04 0.70 
LVEDD 
(mm) 37.50 (7.87) 39.83 (3.1) 2.33 41.00 (6.26) 42.33 (5.78) 1.33 0.77 
1.00 
(-8.44, 6.44) 3.34 0.15 
LVESD 
(mm) 20.67 (5.47) 21.17 (2.4) 0.50 24.67 (6.02) 22.50 (7.37) -2.17 0.32 
2,67 
(-8.31, 2.98) 2.53 0.70 
EF (%)-
mean 72.15 (4.56) 68.92 (5.46) -3.23 68.68 (9.37) 68.72 (7.20) 0.03 0.44 
3.27 
(-5.82, 12.35) 4.08 0.58 
LA Volume 
(ml) 82.82 (31.57) 87.67 (33.45) 9.48 92.38 (25.13) 90.70 (37.03) 0.14 0.72 
9.34 
(-57.22, 38.54) 20.77 0.46 
LVM (g) 233.69 (95.11) 264.49 (118.99) 30.80 323.70 (108.44) 327.65 (106.04) 3.96 0.56 26.86 (-126.80, 73.10) 44.85 0.43 
LVMI 
(g/m2) 109.18 (37.46) 123.17 (52.44) 13.98 157.15 (52.72) 156.08 (44.13) -1.07 0.46 
15.05 
 (-59.00, 28.90) 19.73 0.51 
E (cm/s) 80.03 (20.20) 84.38 (12.87) 4.35 79.38  (18.69) 84.92 (21.36) 5.53 0.90 1.18 (-18.52, 20.90) 8.84 0.07 
A (cm/s) 68.10 (25.55) 66.78 (31.41) -1.32 69.56 (23.29) 63.46 (20.05) -6.10 0.62 4.78 (-25.70, 16.14) 9.34 0.24 
E/A 1.34 (0.72) 1.49 (0.68) 0.14 1.30 (0.37) 1.50 (0.49) 0.19 0.91 0.05 (-0.96, 1.06) 0.44 0.05 
IVRT 
(msec) 79.33 (8.89) 83.75 (12.07) 2.25 72.75 (111.00) 98.40 (29.53) 16.00 0.16 
13.75 
(-29.98, 57.48) 17.01 0.74 
Septal Sa 
(cm/s) 6.45 (2.02) 5.12 (1.99) -1.05 5.30 (0.57) 3.66 (1.15) -1.55 0.65 
0.50 
(-3.20, 2.20) 0.97 0.42 
Septal Ea 
(cm/s) 5.50 (2.45) 5.36 (1.71) -0.15 4.57 (1.00) 3.44 (0.88) -1.00 0.32 
0.85 
(-3.19, 1.50) 0.84 1.10 
Lateral Sa 
(cm/s) 5.46 (2.37) 4.68 (2.05) 0.28 5.04 (1.64) 6.20 (2.26) -0.05 0.30 
0.33 
(-2.70, 2.05) 0.85 0.31 
Lateral Ea 
(cm/s) 6.66 (1.60) 9.28 (3.98) 2.70 5.97 (2.04) 7.90 (4.10) 1.20 0.36 
1.50 
(-9.51, 6.51) 2.89 0.41 
E/e’ ratio 17.28 (10.25) 15.82 (7.47) 0.18 17.15 (3.48) 27.10 (7.80) 11.37 0.02 11.19 (1.21, 21.16) 4.08 2.41 
LVOT 
Gradient at 
rest 
(mmHg) 
8.50 (20.82) 15.73 (28.44) 0.33 3.75 (7.75) 17.60 (34.54) 24.33 0.15 24.00 (-62.03, 110.0) 13.10 29.39 
SAM: N 1 1 0 0 0 0 NA NA NA NA 
All data are presented as mean (SD), unless specified 
* Absolute value of  DPlacebo-DNAC 
Abbreviations: NAC: N-acetylcysteine; M/F: Male/females; CI: Confidence interval; SE: Standard Error; BSA: Body surface area; IVST: 
Interventricular septal thickness; LVPWT: Left ventricular posterior wall thickness; LVEDD: Left ventricular end diastolic diameter; LVESD: 
Left ventricular end systolic diameter; LVEF: Left ventricular ejection fraction; LA: left atrium; LVM: Left ventricular mass; LVMI: Left 
ventricular mass indexed to body surface area; E: Mitral valve early inflow velocities; A: Mitral valve inflow late velocities; IVRT: Isovolumic 
relaxation time; Septal Sa: Systolic mitral annulus velocity measured at septal side of the mitral annulus; Septal Ea: Early diastolic mitral 
annulus velocity measured at septal side of the mitral annulus; Lateral Sa: Systolic mitral annulus velocity measured at lateral side of the mitral 
annulus; Lateral Ea: Early diastolic mitral annulus velocity measured at lateral side of the mitral annulus; LVOT: left ventricular outflow tract 
gradient; SAM: Systolic anterior motion of the mitral leaflet. 
 
 
 
